Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Phase I, interventional, single-arm, open-label, treatment study to evaluate the safety and
effectiveness of CD33-CLL1 CAR in patients with relapsed and/or refractory acute myeloid
leukemia (AML).